TRANSLATE

The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

MANIFEST study: Does the BET inhibitor CPI-0610 show synergy with ruxolitinib in MF?

Featured:

John MascarenhasJohn Mascarenhas

Jun 18, 2020


During the 25th Congress of the European Hematology Association (EHA), the MPN Hub spoke to John Mascarenhas, Icahn School of Medicine at Mount Sinai, New York, US, about the MANIFEST study. We asked: Does the BET inhibitor CPI-0610 show synergy with ruxolitinib in myelofibrosis?

A number of preclinical studies have shown that the two agents work best in combination in murine models of MPN. Furthermore, results from the MANIFEST clinical trial suggest that CPI-0610 + ruxolitinib demonstrates superior clinical activity over the respective monotherapies.

MANIFEST study: Does the BET inhibitor CPI-0610 show synergy with ruxolitinib in MF?